AbbVie’s atogepant meets late-stage goal in menstrual migraine study
AbbVie said its migraine treatment atogepant, branded as Qulipta in the U.S., reduced migraine days associated with the menstrual period in a late-stage study.
AbbVie said on Thursday that its migraine drug reduced migraine days linked to the menstrual period in a late-stage study. S. as Qulipta for migraine prevention in adults. The source text is truncated after stating that the drug met t…